The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

DICP, The Annals of Pharmacotherapy: Vol. 25, No. 5, pp. 505-517.
© 1991 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fields, S.
Right arrow Articles by Koeller, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fields, S.
Right arrow Articles by Koeller, J.

Research Articles

Idarubicin: a second-generation anthracycline

SM Fields and JM Koeller

Because of its in vitro activity in leukemic cell lines and Phase I studies of acute leukemia, Phase II and III clinical trials with idarubicin hydrochloride were conducted in patients with acute lymphocytic leukemia or acute nonlymphocytic leukemia. In the Phase III comparative trials between the combinations of idarubicin and cytarabine and daunorubicin hydrochloride and cytarabine, the idarubicin/cytarabine combination resulted in significantly greater complete remission rates and longer overall survival in two of three studies conducted in the US. As a result, the Food and Drug Administration approved intravenous idarubicin with a Class 1A rating in September 1990 for use in combination with other antileukemic drugs (e.g., cytarabine) for the treatment of acute myelogenous leukemia in adults. The recommended dose of idarubicin is 12 mg/m2 daily for three days by slow intravenous injection in combination with cytarabine. Although idarubicin causes myelosuppression similar to that described with daunorubicin, the incidence of cardiotoxicity in animal models is lower. Idarubicin also has the advantage of oral administration, but the oral formulation of the drug remains investigational. The use of idarubicin in pediatric patients also remains to be established.


This article has been cited by other articles:


Home page
 Ann OncolHome page
D. Crivellari, D. Lombardi, G. Corona, C. Massacesi, R. Talamini, R. Sorio, M. D. Magri, C. Lestuzzi, A. Lucenti, A. Veronesi, et al.
Innovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoring
Ann. Onc., May 1, 2006; 17(5): 807 - 812.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Geroni, M. Ripamonti, C. Arrigoni, F. Fiorentini, L. Capolongo, D. Moneta, S. Marchini, P. D. Torre, C. Albanese, M. G. Lamparelli, et al.
Pharmacological and Toxicological Aspects of 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): A Novel Antineoplastic Agent
Cancer Res., March 1, 2001; 61(5): 1983 - 1990.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
S. Marchini, G. Damia, M. Broggini, G. Pennella, M. Ripamonti, A. Marsiglio, and C. Geroni
4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548), a Novel Anticancer Agent Active against Tumor CellLines with Different Resistance Mechanisms
Cancer Res., March 1, 2001; 61(5): 1991 - 1995.
[Abstract] [Full Text]


homecopy help contact us subscription past issues search current issue
Copyright © 1991 by Harvey Whitney Books Company.